Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth"
Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Disease
About this trial
This is an interventional treatment trial for Metabolic Syndrome focused on measuring Medium chain fatty acids, Saturated fatty acids, Whey protein, Casein protein, Metabolic syndrome, Type 2 diabetes, Cardiovascular disease, Dairy products, Dietary intervention
Eligibility Criteria
Inclusion Criteria:
Metabolic syndrome
- Central obesity (Waist: female ≥ 80 cm; male ≥ 94 cm)
- with two or more of the following
- Fasting triglyceride > 1.7 mmol/l
- HDL-cholesterol; male < 1.03 mmol/l, female < 1.29 mmol/l
- BP ≥ 130/85
- Fasting plasma glucose ≥ 5,6 mmol/l (but not diabetes)
Or abdominal obesity (Waist: female ≥ 80 cm; male ≥ 94 cm)
Exclusion Criteria:
- Significant cardiovascular, renal or endocrine disease
- Psychiatric history
- Treatment with steroids
- Alcohol- or drug-addiction
- Pregnancy or lactation
Sites / Locations
- Aarhus University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Fat rich in MC-SFA
Fat low on MC-SFA
Casein protein
Whey protein
63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.